Deep Intelligent Pharma (DIP), a Beijing-based generative AI company focused on pharmaceutical R&D and clinical trial workflows, has closed a Series D funding round of nearly $50 million. The round was led by Dinghui Baifu, the deeptech investment arm of CDH Investments, with continued participation from existing backers HongShan Capital Group and Xin Ding Capital. The new capital will be used to support DIP’s global expansion and further development of its AI-driven clinical and regulatory solutions.
Redefining Pharmaceutical R&D with AI
Pharmaceutical R&D continues to face long development cycles, high costs, and high failure rates, particularly during clinical development. DIP positions its platform as an intelligent decision-support system designed to address risks in clinical trial design, execution, and regulatory documentation. According to the company, its goal is to improve the overall success rate of drug development by embedding AI into decision-making processes rather than focusing solely on automation.
Founded in 2017, DIP provides AI solutions that support pharmaceutical companies across clinical research, regulatory writing, and data analysis. Founder and CEO Xing Li has stated that the company’s long-term vision is to raise the efficiency and predictability of drug R&D by applying AI at scale to complex clinical workflows.
A Multi-Agent AI Platform for Clinical Workflows
At the core of DIP’s offering is a proprietary multi-agent AI platform designed to break down complex clinical and regulatory tasks into specialized functional components. The company says this architecture allows its system to handle activities ranging from statistical analysis to protocol and documentation generation, while continuously learning from accumulated project data.
DIP claims its platform is built to meet industrial-grade reliability requirements, addressing concerns around inaccuracies commonly associated with general-purpose AI models. This focus on precision is positioned as critical in regulated environments such as clinical trials and regulatory submissions, where errors can have significant consequences.
Strategic Growth and Global Expansion
Proceeds from the Series D round will be used to enhance DIP’s end-to-end clinical AI platform and expand its international commercial presence. The company plans to accelerate overseas deployment of its solutions, with a particular emphasis on supporting Chinese pharmaceutical and biotech companies pursuing global drug development and international regulatory approvals.
DIP reports that it now serves more than 1,000 pharmaceutical and biotech clients globally, including multinational companies such as Johnson & Johnson and Bayer. The company expects continued growth in client numbers and order volume as demand for AI-driven clinical solutions increases worldwide.
Market Validation and Use Cases
According to the company and investor statements, DIP’s platform has been applied in real-world clinical development projects, including international collaborations. One cited example involves work with Immunorock, a Japan-based biotech company, where DIP’s AI tools were used to support clinical trial protocol development and trial design simulation. DIP states that these tools helped shorten development timelines and reduce reliance on traditional contract research workflows.
While these outcomes are presented by the company as evidence of the platform’s effectiveness, DIP emphasizes that its broader value lies in improving consistency, speed, and decision quality across clinical development programs rather than replacing human expertise.
Positioning for the Next Phase of Growth
Investors backing the Series D round highlighted DIP’s systematic approach to applying AI in a highly regulated industry and the competitive barriers created by its data, workflows, and domain specialization. The company expects revenues to grow rapidly, with management indicating that annual revenue could reach several billion Chinese yuan in the near term.
With this funding, Deep Intelligent Pharma aims to scale its operations globally and deepen its role as an AI infrastructure provider for clinical development. The Series D round marks a key milestone as the company seeks to move from domestic leadership to broader international adoption in pharmaceutical R&D.